罕见病知识库 RareSeen

极长链酰基辅酶A脱氢酶缺乏症

Very long chain acyl-CoA dehydrogenase deficiency

定义 英文原文(暂无中文)

Very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency (VLCADD) is an inherited disorder of mitochondrial long-chain fatty acid oxidation with a variable presentation including: cardiomyopathy, hypoketotic hypoglycemia, liver disease, exercise intolerance and rhabdomyolysis.

别名

VLCAD 缺乏症

基本事实

遗传方式
常染色体隐性
发病年龄
婴儿期、新生儿期
患病率
1-9 / 100 000(Europe)

相关基因 1

基因名称关联类型
ACADVLacyl-CoA dehydrogenase very long chainDisease-causing germline mutation(s) in

临床表型 40

常见 79–30%1

  • 循环系统内游离脂肪酸水平增高 HP:0030781

偶见 29–5%15

  • 房间隔缺损 HP:0001631
  • 血清肌酸磷酸激酶升高 HP:0003236
  • 循环肝转氨酶水平升高 HP:0002910
  • 阵发性呼吸急促 HP:0002876
  • 运动诱发的横纹肌溶解 HP:0009045
  • 喂养困难 HP:0011968
  • 肝脏肿大 HP:0002240
  • 低酮性低血糖 HP:0001985
  • 低体温 HP:0002045
  • 黄疸 HP:0000952
  • 超重 HP:0025502
  • 卵圆孔未闭 HP:0001655
  • 呼吸窘迫 HP:0002098
  • 小于胎龄儿 HP:0001518
  • 室间隔缺损 HP:0001629

罕见 <4–1%24

  • 肛门前置 HP:0001545
  • 心律失常 HP:0011675
  • 房室传导阻滞 HP:0001678
  • 扩张型心肌病 HP:0001644
  • 小脑延髓池扩大 HP:0002280
  • 婴儿型肌张力减退 HP:0008947
  • 高氨血症 HP:0001987
  • 低钙血症 HP:0002901
  • 低蛋白血症 HP:0003075
  • 皮肤炎症反应 HP:0011123
  • 昏睡 HP:0001254
  • 巨头畸形 HP:0000256
  • 代谢性酸中毒 HP:0001942
  • 肌肉痉挛 HP:0003394
  • 肥胖 HP:0001513
  • 疼痛 HP:0012531
  • 心包积液 HP:0001698
  • 肺炎 HP:0002090
  • QT间期延长 HP:0001657
  • 心动过速 HP:0001649
  • 呼吸过速 HP:0002789
  • 心室纤颤 HP:0001663
  • 室性心动过速 HP:0004756
  • 呕吐 HP:0002013

近两年的全球研究 135L2

2024/10 起在 Europe PMC 检索所得,按发表时间倒序显示最近 20 篇。标题未译成中文——自动翻译需要接入 LLM 服务,尚未引入。

  • 2026-11开放获取
    Essential Oral Single Nutritional Therapy Products for Inherited Metabolic Diseases: Evidence and Consensus Assessment Using a Modified Delphi Method
    Journal of inherited metabolic disease · DOI · Europe PMC
  • 2026-09综述开放获取
    From Common Pathway to Divergent Diseases: Metabolic Aspects of Inborn Errors of CoA Biosynthesis
    Journal of inherited metabolic disease · 被引 1 · DOI · Europe PMC
  • 2026-08开放获取
    Application of CLIR-Based Post-Analytical Tools to Dutch NBS Data Demonstrates Its Potential Impact on the Performance of CPT1, GA-1, IVA and MSUD Screening in a Disorder-Specific Way
    International journal of neonatal screening · DOI · Europe PMC
  • 2026-08开放获取
    Hormonal Responses to a Short Daytime Fast in Children With Beta-Oxidation Disorders
    JIMD reports · DOI · Europe PMC
  • 2026-08开放获取
    A Case of Suspected Multiple Acyl-CoA Dehydrogenase Deficiency-Induced Encephalopathy
    Case reports in critical care · DOI · Europe PMC
  • 2026-08开放获取
    The Spanish Uniform Newborn Screening Panel (SUSP): A National Consensus Framework for Harmonized Newborn Screening
    International journal of neonatal screening · DOI · Europe PMC
  • 2026-08开放获取
    Medium Chain Acyl-CoA Dehydrogenase Deficiency; an Unexpected Cause of Neonatal Ketoacidosis
    JIMD reports · DOI · Europe PMC
  • 2026-08
    [Screening and genetic variation analysis of fatty acid oxidation disorder in neonates in Qingdao City]
    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pedia · DOI · Europe PMC
  • 2026-07综述开放获取
    The Role of Autophagy in the Pathogenesis of Mitochondrial Diseases
    Cells · DOI · Europe PMC
  • 2026-07开放获取
    Second-Tier Whole Exome Sequencing Following Abnormal Newborn Screening: Diagnostic Yield, Secondary Findings, and Carrier Burden in a Taiwanese Neonatal Cohort
    Children (Basel, Switzerland) · DOI · Europe PMC
  • 2026-07
    Comparison of methods for defatted human milk and nutrient composition: An experimental study
    JPEN. Journal of parenteral and enteral nutrition · DOI · Europe PMC
  • 2026-07病例报告开放获取
    TANGO2-related metabolic encephalopathy-arrhythmia syndrome unmasked in 22q11.2 deletion syndrome: hemizygous pathogenic variant, complex phenotype modified by two genetic conditions, and implications for proactive crisis prevention: a case report
    BMC pediatrics · DOI · Europe PMC
  • 2026-07开放获取
    How to Do Echo in Left Ventricular Hypertrophy: A Consensus Statement of the Italian Society of Echocardiography and Cardiovascular Imaging
    Journal of cardiovascular echography · DOI · Europe PMC
  • 2026-06综述开放获取
    Historical Perspectives, Classification and Diagnostic Approaches of Inborn Errors of Metabolism: A Systematic Review and Meta-Analysis
    Metabolites · DOI · Europe PMC
  • 2026-06综述开放获取
    Next-generation newborn screening: feasibility of combined genetic and biochemical testing for 95 treatable inherited metabolic disorders
    Metabolomics : Official journal of the Metabolomic Society · DOI · Europe PMC
  • 2026-06综述开放获取
    Recent advances in the bioanalysis of acylcarnitines: Methodologies, challenges, and clinical perspectives
    Pharmaceutical science advances · DOI · Europe PMC
  • 2026-06开放获取
    Prenatal Exposure to Persistent Organic Pollutants Is Associated with Altered Lipid and Metabolomic Profiles in Mothers and Newborns
    Environment & health (Washington, D.C.) · DOI · Europe PMC
  • 2026-05病例报告
    Expanding the Mutational Spectrum of &lt;i&gt;ACADVL&lt;/i&gt;: Integrative Characterization of the p.Ser72Phe Variant in Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
    Genes · DOI · Europe PMC
  • 2026-05开放获取
    Expanding the Mutational Spectrum of ACADVL: Integrative Characterization of the p.Ser72Phe Variant in Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
    Genes
  • 2026-05开放获取
    Long-term safety and efficacy of triheptanoin in Korean patients with long-chain fatty acid oxidation disorders: a prospective, open-label, single-center, phase II clinical study
    BMC medical genomics · DOI · Europe PMC

境外已获批用于本病的药物 0L2

欧盟与美国均未检索到已获批用于本病的药物。

尚未获批的在研药物(1 项)

这些药已被欧盟或美国的监管机构认定为罕见病用药(英文 orphan drug designation,中文行业里通称「孤儿药资格」——「孤儿」说的是这类药市场太小、没有厂商愿意认领,不是在说病人)。但这只是一种监管身份:意味着监管机构给予研发上的激励,不代表这个药已被证明有效,也不代表将来一定能上市,绝大多数最终不会成药。列在这里是为了看清有哪些方向正在被尝试。

  • triheptanoin欧盟2015-06-19
    Treatment of very long-chain acyl-CoA dehydrogenase deficiency
    官方记录

数据来自欧洲药品管理局(EMA)的药品与罕见病用药资格公开导出表,以及美国 FDA 的罕见病用药资格数据库(Orphan Drug Product Designation Database)。两边口径不同:欧盟一侧取的是当前状态仍为「已授权」的药品;美国一侧记录的是「曾获批准」这一事实,FDA 的公开表不追踪药物此后是否退市(例如 Relyvrio 于 2024 年撤市,表中仍记为已获批)。请以官方记录页为准。

中国境外的在招试验 4L2

这些试验在中国没有研究中心,通常无法直接报名——入组一般要求在当地居住并接受随访。列在这里是因为它另有用处:看清楚全世界正在试哪些药、做到了哪一期、由谁在做。把药名和 NCT 编号记下来去问主治医生,或据此进一步查该药是否已在境外获批、是否有拓展性用药(expanded access)通道。

以色列1美国1奥地利1德国1意大利1

共 4 项。

  • 招募中NCT06017869
    Evaluate the Safety and Therapeutic Effects of a Single Intravenous Infusion (IV) of Autologous CD34+ Cells Enriched With Allogenic Placenta-derived Mitochondria in Patients With a Diagnosis of Pearson Syndrome (PS)
    II 期 · 干预性 · 2023/07/31Minovia Therapeutics Ltd.
    以色列
  • 招募中NCT04602325
    Systemic Biomarkers of Brain Injury From Hyperammonemia
    观察性 · 2020/07/09Children's National Research Institute
    美国
  • 招募中NCT05554835
    Global Registry and Natural History Study for Mitochondrial Disorders
    观察性 · 2009/02/01LMU Klinikum
    奥地利、德国、意大利
  • 可获取(拓展性用药)NCT03773770
    Expanded Access to Triheptanoin
    拓展性用药Ultragenyx Pharmaceutical Inc

外部标识与链接

发现这一页有错误?告诉我 · 邮件主题会自动带上本页的 ORPHA 编号

本页数据来源

  • 疾病定义、同义词、基因、表型、流行病学:Orphanet(CC BY 4.0)
  • 中文病名:Orphanet 中文包,冻结于 2020-06-01
  • 表型中文标签:HPO 简体中文翻译(CHPO 上游成果)